Harvoni research primary papers
Gilead Sciences is a leading biopharmaceutical company engaged in the discovery, development and commercialisation of innovative therapeutics in areas of unmet medical need. Icahn School of Medicine at Mount Sinai. We are now working to ensure rapid and broad access to Harvoni.". The marketing authorisation application (MAA) for Harvoni was submitted to the European Medicines Agency (EMA) in March 2014. Other medications available for the treatment of chronic hepatitis C include.
Therefore, the purpose of this study is to assess whether Harvoni alone is an effective. Estimated Primary Completion Date : August 30, 2022. The primary objective of this post-marketing surveillance study is to collect and assess data related to the safety and effectiveness of Harvoni. In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor.
LDV/SOF, adult patients with genotypes 1, 4, 5, and 6 chronic HCV infection who take LDV/SOF as part of routine clinical care at a participating clinical site. Those who achieved SVR 12 were considered free from HCV. The most commonly reported adverse reactions in patients treated with Harvoni included fatigue, headache, nausea, diarrhoea, and insomnia. Winston-Salem, North Carolina, United States, 27157. The drug was approved for the treatment of chronic hepatitis C genotype 1 infection by the FDA in October 2014. Contact: Yuvraaj Kapoor,. Please refer to this study by its ClinicalTrials. Developed by Gilead Sciences, Harvoni (ledipasvir/sofosbuvir) is the first combination pill approved for the treatment of adult patients with chronic hepatitis C genotype 1 infection. Harvoni is a two-drug fixed-dose combination product containing 90mg of ledipasvir and 400mg sofosbuvir. Use of ribavirin showed no increase in response rates.